These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10430790)

  • 1. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
    Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A
    Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
    Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
    Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
    Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
    Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary deoxypyridinoline excretion for the evaluation of bone turnover in chronic renal failure.
    Coen G; Mantella D; Calabria S; Sardella D; Manni M; Fassino V; D'Anello E; Giustini M; Taggi F
    Am J Nephrol; 2000; 20(4):283-90. PubMed ID: 10970981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
    Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
    Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
    Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms.
    Magnusson P; Sharp CA; Magnusson M; Risteli J; Davie MW; Larsson L
    Kidney Int; 2001 Jul; 60(1):257-65. PubMed ID: 11422759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.
    Coen G; Ballanti P; Bonucci E; Calabria S; Centorrino M; Fassino V; Manni M; Mantella D; Mazzaferro S; Napoletano I; Sardella D; Taggi F
    Nephrol Dial Transplant; 1998 Sep; 13(9):2294-302. PubMed ID: 9761512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of new markers of bone formation and resorption in kidney transplant recipients.
    Małyszko J; Wołczyński S; Małyszko JS; Konstantynowicz J; Kaczmarski M; Myśliwiec M
    Transplant Proc; 2003 Jun; 35(4):1351-4. PubMed ID: 12826157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone turnover in hyperthyroidism before and after thyrostatic management.
    Isaia GC; Roggia C; Gola D; Stefano MD; Gallone G; Aimo G; Ardissone P; Mussetta M
    J Endocrinol Invest; 2000 Dec; 23(11):727-31. PubMed ID: 11194705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic validity of bone metabolic markers for bone metastasis.
    Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
    Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin.
    Sairanen S; Tähtelä R; Laitinen K; Karonen SL; Välimäki MJ
    Calcif Tissue Int; 1994 Nov; 55(5):349-52. PubMed ID: 7866915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.